Home » Newsletters » BioWorld

BioWorld

Oct. 8, 2004

View Archived Issues

Senate Hearing Discusses Pros, Cons Of BioShield II

Acuity Pharmaceuticals Touts RNAi Trial As Historic First'

FDA Puts TNFerade On Hold; GenVec Stock Takes Nosedive

rAAT Phase II Study Misses In Atopic Dermatitis; ProMetic Falls

Other News To Note

Theravance Prices $98M IPO; Three Others Raise $85M Total

The first full week of October proved to be a busy one for financings in the biotechnology world. (BioWorld Today) Read More

Genentech's 3Q Earnings Top Consensus Estimates

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 6, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 6, 2025.
Regenxbio’s Duchenne gene therapy data positive as shares falter
BioWorld
Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
EMA warns Ozempic linked to ‘very rare’ side effect
BioWorld
The EMA’s safety committee has issued a warning that the GLP-1 receptor agonist Ozempic (semaglutide, Novo Nordisk A/S) can cause an acute eye condition in which...
Aiatella secures €2M for AI-based cardiovascular imaging tech
BioWorld MedTech
Aiatella Oy secured €2 million (US$2.28 million) in funding for its AI-powered cardiovascular imaging technology. The funds will be used to conduct clinical...